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ABSTRACT 
Objective: The study is directed towards the development of an orally disintegrating drug delivery system of memantine hydrochloride which can 
be commercially exploited for the well-being of society for the treatment of Alzheimer’s disease, which is a most common form of dementia. 
Methods: Orally disintegrating immediate-release tablets of memantine hydrochloride were prepared and optimized for disintegration time and in 
vitro drug release. The top spray granulation method was used for the preparation of granules. Subsequently, these granules were compressed to 
tablets. The levels of diluent, disintegrant and taste-masking agents were optimized using the design of experiments. The resulting tablets were 
evaluated for disintegration time and in vitro drug release. The optimized formulation was subjected to accelerated stability study for 3 mo. 
Results: The optimized orally disintegrating tablet formulation exhibited a disintegration time of 2-3 min and complete drug release i.e. more than 
85 % drug release within 10 min while performing in vitro drug release study. This is a prerequisite for faster action in the case of patients suffering 
from Alzheimer’s disease. Accelerated stability studies indicated good physical and chemical stability of the optimized formulation. 
Conclusion: Developed orally disintegrating tablet formulation of memantine hydrochloride could release the drug faster compared to 
conventional immediate-release tablets which is useful in paediatric, geriatric and psychiatric patients. 
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INTRODUCTION 
Dementia is a syndrome in which there is the disturbance of multiple 
higher cortical functions, including memory, thinking, orientation, 
comprehension, calculation, learning capacity, language, and judgment 
[1, 2]. Alzheimer’s disease is the most common form of dementia, which 
is the major cause of disability in later life and accounts for 11.9 % of the 
years lived with disability due to a non-communicable disease [3, 4]. In 
the early stages of the disease, people most often notice memory 
problems that can be severe enough to interfere with their ability for 
routine tasks and work [5, 6]. In this disease, the change in forgetfulness 
is more dramatic than normal which commonly gets increased with age. 
More importantly, this difficulty is persistent, progressive, and severe 
and there is usually a noticeable, rapid decline in cognitive skills [7, 8]. 
Alzheimer’s disease is further classified into two types, one is a familial 
type that is passed from one generation to another through a 
dominant gene, is very rare and is seen in only 5-10 % of cases. About 
90 % of cases are the sporadic type, which can be developed even if 
nobody in the family has had the disease [9, 10]. In the United States, it 
is the fourth leading cause of death and the most common cause of 
dementia. The total number of people with dementia worldwide is 
projected to nearly double every 20 y, 65.7 million in 2030 and 115.4 
million in 2050 [11-13]. The total number of new cases each year 
worldwide is nearly 7.7 million, implying one new case every 4 
seconds. The fastest growth is taking place in China, India, and their 
south Asian and western Pacific neighbours. It is projected that by 
2050, people aged 60 and over will account for 22 % of the world’s 
population with 80 % living in Asia, Latin America or Africa [14]. 
Memantine hydrochloride is a low-moderate affinity, uncompetitive 
n-methyl-d-aspartate (NMDA) receptor antagonist with strong 
voltage dependency and rapid blocking/unblocking kinetics [15, 16]. 
These pharmacological features appear to allow memantine to block 
the sustained activation of the receptor by glutamate that may occur 
under pathological conditions, and to rapidly leave the NMDA 
receptor channel during normal physiological activation.  
Current approach is intended to develop an orally disintegrating 
drug delivery system of memantine hydrochloride which is gaining 
importance in the field of pharmaceutical technology as these 
systems are beneficial for many patients particularly from paediatric 
and geriatric populations who have difficulty in swallowing 
conventional tablets and capsules and also in patients travelling 
with little or no access to water, leading to non-compliance and 
ineffective therapy [17, 18]. 
MATERIALS AND METHODS 
Chemicals and reagents 
Memantine hydrochloride was obtained as a gift sample from Cadila 
Healthcare Ltd, Mumbai, India; microcrystalline cellulose, mannitol, 
croscarmellose sodium, silica colloidal anhydrous and magnesium 
stearate procured from Signet chemicals ltd, Eudragit EPO as a gift 
sample from Evonik GmbH, India. All these suppliers were based in 
Mumbai, India. 
Methods 
Analytical development  
The analytical development was carried out by a high-performance 
liquid chromatography (HPLC) method using HPLC system 
(Shimadzu LC2010C, UV Detector) equipped with a column (Zorbax 
SB C18, 4.6 × 50 mm, 3.5 µm). 
Preparation of orally disintegrating tablets of memantine 
hydrochloride 
Initial developmental trials to formulate the orally disintegrating 
tablets of memantine hydrochloride were taken to select excipients 
and their primary levels. The taste and flavour enhancers were used 
with wet granulation technique to mask the bitterness of the drug. 
Based on the observations and results of these trials, actual 
optimization batches were planned (table 1a and 1b). 
Manufacturing process 
Memantine hydrochloride, microcrystalline cellulose, mannitol were 
sifted through # 40 sieve and transferred to the bowl of top spray 
granulator. Eudragit EPO ready mix clear was dispersed in purified 
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water and used to spray on the blend by top spray granulation 
method and subsequently dried. The dried granules were milled 
using a suitable screen and blended with sifted extra granular 
materials viz. croscarmellose sodium, silica colloidal anhydrous, 
tartaric acid, neotame, acesulfame potassium and tutti-frutti flavour. 
The blend was lubricated with magnesium stearate in the blender. 
The lubricated blend was transferred to the hopper of the 
compression machine and tablets were compressed at the hardness 
of 2-4 kg/cm2
 
 using 8 mm circular, flat-faced bevelled edge, plain 
punches using Cadmach single rotary compression machine. 
Table 1a: Composition of optimization trials (F1-F7) 
Ingredients F1 F2 F3 F4 F5 F6 F7 
mg/tablet 
Memantine hydrochloride 5.000 5.000 5.000 5.000 5.000 5.000 5.000 
Microcrystalline cellulose 85.650 103.650 83.650 59.650 103.650 63.650 67.650 
Mannitol 40.000 20.000 40.000 60.000 20.000 60.000 60.000 
Eudragit EPO Ready mix Clear 2.000 4.000 4.000 6.000 2.000 4.000 2.000 
Purified water q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
Croscarmellose sodium 4.000 4.000 4.000 6.000 6.000 4.000 2.000 
Silica colloidal anhydrous 1.450 1.450 1.450 1.450 1.450 1.450 1.450 
Tartaric acid 3.500 3.500 3.500 3.500 3.500 3.500 3.500 
Tutti-frutti flavour 4.500 4.500 4.500 4.500 4.500 4.500 4.500 
Neotame 1.500 1.500 1.500 1.500 1.500 1.500 1.500 
Acesulfame potassium 0.900 0.900 0.900 0.900 0.900 0.900 0.900 
Magnesium stearate 1.500 1.500 1.500 1.500 1.500 1.500 1.500 
 
Table 1b: Composition of optimization trials (F8-F15) 
Ingredients F8 F9 F10 F11 F12 F13 F14 F15 
mg/tablet 
Memantine hydrochloride 5.000 5.000 5.000 5.000 5.000 5.000 5.000 5.000 
Microcrystalline cellulose 103.650 81.650 63.650 81.650 99.650 107.650 63.650 85.650 
Mannitol 20.000 40.000 60.000 40.000 20.000 20.000 60.000 40.000 
Eudragit EPO Ready mix Clear 6.000 6.000 2.000 4.000 6.000 2.000 6.000 4.000 
Purified water q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
Croscarmellose sodium 2.000 4.000 6.000 6.000 6.000 2.000 2.000 2.000 
Silica colloidal anhydrous 1.450 1.450 1.450 1.450 1.450 1.450 1.450 1.450 
Tartaric acid 3.500 3.500 3.500 3.500 3.500 3.500 3.500 3.500 
Tutti-frutti flavour 4.500 4.500 4.500 4.500 4.500 4.500 4.500 4.500 
Neotame 1.500 1.500 1.500 1.500 1.500 1.500 1.500 1.500 
Acesulfame potassium 0.900 0.900 0.900 0.900 0.900 0.900 0.900 0.900 
Magnesium stearate 1.500 1.500 1.500 1.500 1.500 1.500 1.500 1.500 
  
Evaluation of blend 
The lubricated blend was evaluated for flow characteristics: bulk 
density (BD), tapped density (TD), compressibility index (CI), 
Hausner’s ratio (HR) and angle of repose. The flow characteristics 
were determined by using approximately 25 g weighed amount of 
blend in 100 ml measuring cylinder.  
Evaluation of tablets  
The formulations were evaluated for hardness, weight variation, 
thickness, friability, disintegration time, disintegration time in the oral 
cavity, in vitro dispersion time, wetting time and water absorption 
ratio, assay, content uniformity and in vitro dissolution study. 
Tablet hardness 
Hardness is the crushing strength of a tablet which determines the 
ease of handling and the rigors of the transportation. For each 
formulation, 10 tablets were used for the study.  
Weight variation test  
The weight variation test was done by weighing 20 tablets 
individually, calculating the average weight and comparing the 
individual tablet weight to the average. The table given below shows 
the weight variation tolerance for uncoated tablets.  
Thickness  
The thickness of the tablets was measured using digital vernier caliper.  
Friability  
Friability test is performed to assess the effect of friction and shocks, 
which may often cause the tablet to chip, cap or break. Roche 
friabilator was used for this purpose. This device subjects the tablets 
to the combined effect of abrasion and shock by utilizing a plastic 
chamber that revolves at 25 rpm dropping the tablets at a distance 
of 6 inches with each revolution. The pre-weighed sample of tablets 
was placed in the friabilator, which was then operated for 100 
revolutions. Tablets were dedusted and re-weighed.  
Disintegration time  
One tablet was placed in each of six tubes of the disintegration test 
apparatus. Disintegration test was carried out at 37±2 °C according 
to United States Pharmacopoeia (USP) 22nd
Disintegration time in oral cavity  
 edition. The time 
required for the complete passage of tablet fragments through the 
sieve (#10) was considered as the disintegration time of the tablet.  
The disintegration time in the oral cavity of 6 human volunteers was 
measured by placing the tablet on the tongue until no lumps remain. 
It is expressed in seconds [17]. 
In vitro dispersion time  
In vitro dispersion, time was measured by dropping tablets in 100 
ml of water and stirring until completely dispersed. A smooth 
dispersion is produced which passes through a screen with a 
nominal mesh aperture of 710 μm.  
Wetting time and water absorption test  
Wetting time is closely related to the inner structure of tablets and 
to the hydrophilicity of the excipients. According to the following 
equation proposed by Washburn E. W., the water penetration rate 
into the powder bed is proportional to the pore radius and is 
affected by the hydrophilicity of the powder. It is obvious that pore 
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size becomes smaller and wetting time increases with an increase in 
compression force or a decrease in porosity. A linear relationship 
exists between wetting time and disintegration time. Thus, wetting 
time is an important step in the disintegration process to take place.  
A piece of tissue paper folded twice was placed in a small petri dish 
(internal diameter = 6.5 cm) containing 6 ml of water. A tablet was 
placed on the paper, and the time for complete wetting of the tablet 
was measured in seconds. The method was slightly modified by 
maintaining water at 37 °C [17].  
The same procedure was repeated for determining the water absorption 
ratio. The wetted tablet was then weighed. Water absorption ratio, R, 




 = Weight of tablet before study.  
b
Assay  
 = Weight of tablet after study. 
30 tablets were randomly selected from each batch. Out of 30 
tablets, 10 tablets were crushed into fine powder. Powder 
equivalent to label claim was weighed accurately, dissolved in the 
media and analyzed for assay. 
Uniformity of dosage units (By content uniformity) 
One tablet was taken in 100 ml volumetric flask, which was shaken 
with 15 ml of methanol and sonicated for 10 min. 15 ml of 0.2 N 
sodium hydroxide solution was added and sonicated for 15 min with 
vigorous shaking. 10 ml of internal standard solution was added and 
shaken for 15 min and then allowed to separate 2 layers for about 
15 min. The top toluene layer was separated by using pasture 
pipette and dried over anhydrous sodium sulphate. The initial 2-3 
ml was discarded and remaining solution was used for analysis. 
In vitro dissolution studies 
The in vitro dissolution study was carried out using 900 ml of 0.01 N 
HCl at 37±0.5 °C temperature at 50 rpm using USP Type 2 (paddle) 
dissolution test apparatus. Samples were withdrawn at 1, 2, 4, 6, 8, 
and 10 min time intervals. 
Reproducibility of optimized composition trial and accelerated 
stability studies 
Reproducible batch was prepared similar to the composition of 
optimized batch in order to evaluate the reproducibility and the 
stability profile of the formulation. The tablets were packed in blisters 
and subjected to accelerated storage conditions of 40 °C/75 % RH. 
Samples were evaluated at the time intervals of 1, 2 and 3 mo [17]. 
Statistical analysis 
One way analysis of variance (ANOVA) was employed to assess 
difference between the assay values of initial and that of stability 
samples using Sigma stat software (Sigma stat 2.03, SPSS). Similar 
statistical test was applied to find the difference in the in vitro drug 
release at each time point among stability samples. The observed p 
values using ANOVA were considered for determining the statistical 
significance for the assay and in vitro drug release at each time point 
among stability samples. 
RESULTS AND DISCUSSION 
Calibration curve 
The linearity for memantine hydrochloride was demonstrated over 
the range of 50 % to 150 % of the label claim. The plot was found to 
be linear with a correlation coefficient of 0.99996 and y-intercept of 
1.4 % with respect to 100 % linearity level response. 
Formulation development  
Evaluation of tablets  
Most of the earlier work by various authors involved development of 
the orally disintegrating tablets of memantine hydrochloride by 
OVAT (One variable at a time) approach [17]. In this study, 15 trials 
were performed with respect to the design of experiments and 
observed parameters for the same have given in table 2, 3 and 4. The 
tablets were compressed at the target weight. The weight variation 
range was observed at target weight±5 %, which falls within the 
acceptable weight variation range of±7.5 % as per USP. Hence, all 
formulations complied with the weight variation test indicating the 
minimal impact of formulation compositions. The hardness of all 
formulations was observed in the range of 2.5–4.0 kg/cm2. 
Generally, an increase in the concentration of polymer contributes to 
higher hardness values; however, it is not an absolute indicator of 
strength [17]. 
Disintegration time is a very important parameter of fast 
disintegrating tablets. The internal structure of a tablet, pore size 
distribution, water penetration into tablet and swelling of 
disintegrant are key aspects to determine the mechanism of 
disintegration. The disintegration time of formulation was satisfying 
because it disintegrated in the range of 1 to 4 min. The trial, F10 
demonstrated the best disintegrating time, i.e. 61±2.08 s (table 3) 
which depicts the impact of high concentration of mannitol and 
croscarmellose sodium. But the lubricated blend of this batch was 
found to have poor flow characteristics, as the mannitol 
concentration used in this trial was very high. The mannitol has poor 
flow and binding properties. Trial F1, having a lower concentration 
of binder, was not able to yield sufficient hardness, whereas, lower 
drug content in trial F2 could be attributed to the segregation as a 
result of vast differences in ratio of diluents (microcrystalline 
cellulose: mannitol). The trials F6, F7, F12 and F13 exhibited poor 
flow characteristics. The trial F5 also showed a lower disintegration 
time of 64±2.13 s, but found to comprise of the lower assay value. 
Trials F4, F7, F8, F9, F12, F13, F14 and F15 were found to have less 
than 90 % dissolution in 10 min. Trial F10 and F11 depicted lower 
disintegration time and complete drug release but at the cost of 
higher concentration of mannitol and croscarmellose sodium, which 
was not worthwhile. The percentage drug content (assay) of 
formulation F1–F15 was found to be 92.0±2.59 % w/w to 99.8±0.23 
% w/w (table 2, 3 and 4) which is within the acceptable limits as per 
individual monograph of selected drugs. In vitro dispersion time was 
measured by the time taken to undergo uniform dispersion as per 
the British Pharmacopoeia. The rapid dispersion was observed in 
the trial F10 indicating better disintegrating properties of 
croscarmellose sodium. It also revealed the effect of mannitol and 
microcrystalline cellulose combination along with aqueous solvent 
on the tablet characteristics. Wetting time corresponds to the time 
taken for the tablet to disintegrate when kept motionless on the 
tongue. Some individuals have the tendency to chew or crush the 
tablet after keeping in the oral cavity. This is the reason that the 
disintegration time in the oral cavity and the wetting values do not 
coincide. It was observed that the pore size get smaller due to an 
increase in compression force, and hence, wetting time increases 
due to decrease in porosity. A linear relationship exists between 
wetting time and disintegration time. Even though, wetting time is 
considered very valuable parameters to assess the disintegration 
time. The wetting time of formulation F1–F15 was found in the 
range of 109.1±0.85 s to 289.1±1.15 s. This may be due to the ability 
of swelling and water absorption capacity [18]. The water 
absorption ratio is closely related to the inner structure of tablets. 
The water absorption ratio values of formulation F1–F15 were 
found to be 51.1±0.9 to 136.2±1.2. The wide range of these values 
attributed to the difference in the concentrations of mannitol and 
croscarmellose sodium in each trial. Croscarmellose sodium is a very 
effective super disintegrant as it allows water penetration into 
tablets through the hydrophilic, fibrous particles and the subsequent 
development of a strong disintegration force. It avoids lump 
formation on disintegration. 
The hardness of all formulations was kept constant 
within the above-mentioned range by adjusting the compression 
force in order to compare the disintegration time of the formulations 
prepared using different compositions. The friability of none of the 
formulations exceeded 0.517 %. The friability data indicate that the 
tablets were mechanically stable and could handle the rigors of 
transportation and handling. The thickness of all formulations was 
observed between 2.60–2.88 mm indicating fairly acceptable 
tabletting. 
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In vitro dissolution study  
The dissolution study on formulation F1–F15 showed the 
dissolution ranging 74±2.27 % to 100±1.09 % in 10 min (table 2-4 
and fig. 1). High dissolution resulted due to faster breakdown and 
rapid dispersion of the tablet. It may be due to rapid diffusion or the 
porous nature of the tablet. The dissolution graphs shown in fig. 1 
depict the same. Based on the data, it can be concluded that the 
addition of super disintegrant improved the dissolution profile of 
the water-soluble drug besides expediting the disintegration time. 
 
Table 2: Physico-chemical characteristics of formulation F1 to F5 
Parameters F1 F2 F3 F4 F5 
Bulk density (g/ml) 0.467 0.498 0.477 0.389 0.396 
Tapped density (g/ml) 0.556 0.612 0.538 0.497 0.492 
Compressibility Index (%) 16.007 18.627 11.338 21.730 19.512 
Hausner’s ratio 1.191 1.229 1.128 1.278 1.242 
Angle of repose 27.9 31.2 26.8 29.5 31.2 
Weight variation (mg) 150±4 150±3 150±1 150±2 150±2 
Thickness (mm) 2.75±0.06 2.75±0.08 2.70±0.08 2.75±0.04 2.80±0.08 
Friability (%) 0.419 0.208 0.234 0.312 0.419 
Hardness (kg/cm2 2.8±0.4 ) 3.4±0.2 3.6±0.4 2.7±0.3 3.5±0.4 
Disintegration time (s) 93±3.05 118±2.32 104±1.04 140±3.21 64±2.13 
Dispersion time (s) 113±2.17 138±1.01 126±2.95 157±1.89 99±1.29 
Content uniformity (%) 97.2±1.2 91.4±2.9 98.8±2.1 95.0±1.37 92.6±3.20 
Water absorption ratio 58±0.8 69.6±1.2 63.5±1.1 79.2±1.2 53.1±1.9 
Assay (% w/w) 97.3±1.12 95.4±2.87 98.9±0.93 97.1±1.27 93.2±2.23 
Wetting time (s) 127.1±1.12 152.6±1.55 139.6±1.18 180.0±1.09 110.0±3.1 
Dissolution (%) 99±1.03 94±2.23 91±1.51 84±2.05 97±0.98 
Values are represented as mean±standard deviation, n = 3 for assay, n = 6 for dissolution and n = 10 for all physical parameters. 
 
Table 3: Physico-chemical characteristics of formulation F6 to F10 
Parameters F6 F7 F8 F9 F10 
Bulk density (g/ml) 0.315 0.322 0.378 0.477 0.398 
Tapped density (g/ml) 0.466 0.451 0.488 0.543 0.478 
Compressibility Index (%) 32.403 28.603 22.541 12.155 16.736 
Hausner’s ratio 1.479 1.401 1.291 1.138 1.201 
Angle of repose 26.3 28.4 34.3 28.5 26.6 
Weight variation (mg) 150±2 150±1 150±5 150±3 150±4 
Thickness (mm) 2.65±0.04 2.68±0.04 2.80±0.05 2.70±0.06 2.68±0.07 
Friability (%) 0.277 0.293 0.437 0.119 0.258 
Hardness (kg/cm2 2.7±0.2 ) 2.8±0.3 3.0±0.5 3.3±0.4 3.0±0.3 
Disintegration time (s) 118±1.48 118±3.65 228±2.11 205±1.10 61±2.08 
Dispersion time (s) 138±2.15 152±0.95 252±2.17 238±2.11 98±1.10 
Content uniformity (%) 98.3±1.70 91.1±1.90 96.2±3.20 99.5±2.10 98.7±1.50 
Water absorption ratio 64.3±1.4 70.1±1.0 132.3±1.8 132.0±1.4 51.1±0.9 
Assay (% w/w) 97.6±1.08 92.0±2.59 95.5±1.99 99.8±0.23 98.9±0.67 
Wetting time (s) 148.1±1.15 162.5±2.10 263.1±1.12 258.1±1.75 109.1±0.85 
Dissolution (%) 96±1.12 87±1.23 78±1.17 80±2.21 100±1.09 
Values are represented as mean±standard deviation, n = 3 for assay, n = 6 for dissolution and n = 10 for all physical parameters. 
 
Table 4: Physico-chemical characteristics of formulation F11 to F15 
Parameters F11 F12 F13 F14 F15 
Bulk density (g/ml) 0.481 0.337 0.331 0.357 0.469 
Tapped density (g/ml) 0.539 0.499 0.517 0.504 0.537 
Compressibility Index (%) 10.761 32.465 35.977 29.167 12.663 
Hausner’s ratio 1.121 1.481 1.562 1.412 1.145 
Angle of repose 26.1 29.1 32.8 30.7 26.9 
Weight variation (mg) 150±1 150±2 150±5 150±2 150±3 
Thickness (mm) 2.70±0.06 2.65±0.05 2.78±0.05 2.68±0.06 2.70±0.06 
Friability (%) 0.311 0.517 0.473 0.336 0.112 
Hardness (kg/cm2 3.4±0.3 ) 3.2±0.3 3.5±0.5 2.8±0.3 3.4±0.3 
Disintegration time (s) 84±1.27 125±0.31 112±1.12 235±2.36 195±1.47 
Dispersion time (s) 108±1.46 145±2.05 139±3.17 267±3.19 218±2.15 
Content uniformity (%) 98.3±1.70 94.5±4.20 93.6±1.90 98.3±1.70 98.3±1.70 
Water absorption ratio 54.3±1.1 72.1±1.9 70.0±1.5 136.2±1.2 109.1±1.8 
Assay (% w/w) 97.6±1.12 96.1±2.10 94.3±3.12 98.8±0.78 99.0±0.44 
Wetting time (s) 119.3±1.37 161.3±1.07 148.9±1.01 289.1±1.15 228.6±1.30 
Dissolution (%) 98±3.01 86±1.09 89±1.61 74±2.27 85±1.17 
Values are represented as mean±standard deviation, n = 3 for assay, n = 6 for dissolution and n = 10 for all physical parameters. 
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Fig. 1: Dissolution profile for optimization batches (mean±SD, n = 3) 
 
Reproducibility of optimized composition trial and accelerated 
stability studies 
The reproducibility was evaluated for batch F3 with respect to assay 
and dissolution profile. Stability samples when evaluated at various 
time intervals, showed no significant difference in appearance, 
hardness or other physical traits as compared to initial samples 
(table 5). The statistical analysis of assay values of stability samples 
indicated no significant difference. In vitro release profile of samples 
when compared with that of initial using ANOVA, exhibited no 
significant difference. Thus, indicating overall good stability of the 
formulation at accelerated conditions. 
 
Table 5: Evaluation of stability sample 
Test Specification Initial 1 mo 2 mo 3 mo 
Description White to off-white 
coloured round, 
biconvex tablets 
White to off-white 
coloured round, 
biconvex tablets 
White to off-white 
coloured round, 
biconvex tablets 
White to off-white 
coloured round, 
biconvex tablets 
White to off-white 
coloured round, 
biconvex tablets 
Average weight 150 mg±3 % complies complies Complies Complies 
Hardness 3–7 kg/cm 3.5–6 kg/cm2 3.5–5 kg/cm2 3–5 kg/cm2 3–4.5 kg/cm2 
Disintegration time 
2 
30–180 s 115 s 110 s 110 s 100 s 
Assay 90-110 % 99.9±0.5 % 99.1±0.8 % 98.7±1.2 % 98.1±2.0 % 
Drug release NLT 85 % 92.8 % 92.1 % 91.6 % 91.0 % 
Values of assay and drug release are represented as mean±standard deviation, n = 3, n = 6 respectively. 
 
CONCLUSION  
Memantine hydrochloride mouth dissolving tablet formulation was 
manufactured by the top spray granulation method and subsequent 
compression to tablets. Various compositions with different 
excipients and their levels were used, among them, F3 was found to 
be the best formulation which showed satisfactory results for the 
tests conducted. Based on the evaluation parameters like friability, 
dispersion test, wetting time disintegration time in the oral cavity 
and in vitro dissolution study, F3 was found to be optimized 
formulation with a disintegration time of 104±1.04 s and release of 
the drug was 91±1.51 % within 10 min indicating a better in vitro 
drug release when compared to other formulations. 
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